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Abstract: This study was designed to investigate a possible role of the N-terminal tripeptide
of insulin-like growth factor-1 (IGF-I), Gly-Pro-Glu (GPE), physiologically generated in neurons
following IGF-I-specific cleavage, in promoting neural regeneration after an injury. Primary cultures
of mouse neural stem cells (NSCs), obtained from 13.5 Days post-conception (dpc) mouse embryos,
were challenged with either GPE, growth hormone (GH), or GPE + GH and the effects on cell
proliferation, migration, and survival were evaluated both under basal conditions and in response
to a wound healing assay. The cellular pathways activated by GPE were also investigated by using
specific chemical inhibitors. The results of the study indicate that GPE treatment promotes the
proliferation and the migration of neural stem cells in vitro through a mechanism that involves the
activation of extracellular signal-regulated kinase (ERK) and phosphoinositide 3-kinase PI3K-Akt
pathways. Intriguingly, both GPE effects and the signaling pathways activated were similar to those
observed after GH treatment. Based upon the results obtained from this study, GPE, as well as GH,
may be useful in promoting neural protection and/or regeneration after an injury.
Keywords: GPE; GH; neural regeneration; ERK; PI3K/Akt; N-methyl-D-aspartate (NMDA); neural
stem cells; brain injury
1. Introduction
Besides its role as a critical mediator of body growth and development [1,2], the insulin-like
growth factor-1 (IGF-1) plays also a prominent role in central nervous system (CNS) development and
metabolism. IGF-1 is necessary for the normal development of the brain, as revealed by the striking
CNS phenotype observed in both IGF-1−/− mice and transgenic mice overexpressing IGF-1 [3]. In the
adult life, IGF-1 continues to exert a prominent role in regulating many CNS functions including
neuromodulation, neuroprotection, neural plasticity, and neural repair [4–7]. Owing to these actions,
IGF-1 has been proposed as a novel therapeutic in several neurological disorders, although its clinical
application is limited by its large molecular size, poor central uptake, and mitogenic potential.
Within the brain, IGF-1 is proteolytically processed by a specific acid protease, generating
des-N-(1-3)-IGF-1 (des-IGF-1), and an N-terminal Gly-Pro-Glu tripeptide (GPE) [8–10]. Although GPE
was initially considered to be a non-bioactive by-product of IGF-1, it was later found that this small peptide
was able to significantly increase the release of ACh from rat cortical slices [11,12]. Consequently,
several neuroprotective effects of GPE have been unveiled since that discovery (see [13–15] for
review). Thus, GPE has been shown to protect hippocampal neurons from NMDA-induced toxicity
in vitro [11], and to reduce brain injury after hypoxia-ischemia [16–18]. In addition, GPE has been
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found to exert neuroprotective actions in animal models of neurodegenerative processes, such as
Huntington’s, Parkinson’s, or Alzheimer’s diseases [19–21]. Finally, GPE shows an anti-depressant
activity in lipopolysaccharide (LPS)-induced depression in mice [22].
However, the possibility that GPE would also be involved in the regulation of the proliferation
of neural stem cells (NSCs) and, therefore, have a potential role in neural regeneration has not been
described so far. In this study, we have investigated the effect of GPE on the regulation of the
proliferation and survival of mouse embryonic NSCs in vitro. For comparison purposes, we also
analyzed the effects of growth hormone (GH) on these cultured cells, because in previous studies
we showed that exogenous GH cooperates with locally-produced GH in increasing the proliferation
of hippocampal neural stem cells after an injury [23], and we established the signaling pathways by
which GH leads to cell proliferation and survival in hippocampal neural precursors [24]. Moreover,
the positive effects of GH on brain are well known [25].
Our results demonstrate that GPE exerts a positive effect on the proliferation and survival of
NSCs that is mediated, at least in part, via activation of the extracellular signal-regulated kinase (ERK)
and phosphoinositide 3-kinase (PI3K)-Akt pathways.
2. Results
2.1. Neural Differentiation In Vitro
Depending on the culture conditions, cells isolated from 13.5 dpc (days post conception) mouse
embryo brains can give rise to new neurospheres upon passaging or differentiate into cells expressing
characteristic markers of the three neural cell types, i.e., neurons, astrocytes, and oligodendrocytes cells
(Figure 1). In addition, a significant number of cells express SOX2, a member of the SoxB1 transcription
factor family that is expressed in neural progenitor populations throughout development and is
necessary to maintain a neural progenitor state [26]. Altogether, these findings reveal the potential for
multi-lineage differentiation of neural cells isolated from 13.5 dpc mouse embryos, and validates their
NSC phenotype.
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Figure 1. Characterization of mouse embryonic neural stem cell (NSC) cultures. Cells obtained from 
13.5 dpc (days post conception) mouse embryo brains were placed into glass coverslips and cultured 
as indicated. Growing the cells in the presence of semi-synthetic medium containing epidermal 
growth factor (EGF) and basic fibroblast growth factor (bFGF) resulted in the formation of 
neurospheres (A) that could be differentiated to monolayer cultures after withdrawn of the factors 
(B,C). Immunoreactivity against specific markers of the three neural lineages (i.e., neurons, astrocytes, 
and oligodendrocytes) was revealed in the differentiated cells by using specific antibodies against 
anti-glial fibrillary acidic protein (GFAP) (D), myelin basic protein (MBP) (E), and NeuN (F). Notice 
that a significant number of cells retain anti-SOX2 immunoreactivity (G). Scale bars 100 µm (A,C–F) 
or 50 µm (B). 
Figure 1. Characterization of mouse embryonic neural stem cell (NSC) cultures. Cells obtained from
13.5 dpc (days post conception) mouse embryo brains were placed into glass coverslips and cultured as
indicated. Growing the cells in the presence of semi-synthetic medium containing epidermal growth
factor (EGF) and basic fibroblast growth factor (bFGF) resulted in the formation of neurospheres (A) that
could be differentiated to monolayer cultures after withdrawn of the factors (B,C); Immunoreactivity
against specific markers of the three neural lineages (i.e., neurons, astrocytes, and oligodendrocytes)
was revealed in the differentiated cells by using specific antibodies against anti-glial fibrillary acidic
protein (GFAP) (D); myelin basic protein (MBP) (E); and NeuN (F); Notice that a significant number of
cells retain anti-SOX2 immunoreactivity (G); Scale bars 100 µm (A,C–F) or 50 µm (B).
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2.2. Cell Proliferation Induced by Gly-Pro-Glu (GPE) or Growth Hormone (GH)
Treatment of primary NSC cultures with 100 µM GPE induced a significant increase in the number
of BrdU+ cells (Figure 2A,B). This effect was similar to that observed when cells were treated with GH,
however, surprisingly, co-treatment with GPE + GH did not elicit any further increase in the number
of proliferating cells as compared with the isolated effect of each of them (Figure 2A,B). Similar results
were obtained when cell proliferation was determined in a wound-healing assay (Figure 2C–D2).
Also in this case, treatment with either GPE or GH induced a significant increase in the number of
BrdU+ cells present at the edges of the wound, but further increases in the number of BrdU+ cells were
not observed when both hormones were given simultaneously.
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a scratch wound healing assay was performed (see methods for further details); (C,E) Each bar 
represents the mean + SEM of three independent experiments (n = 30); (D1,D2) Representative images 
of results are shown in panels (C,E) after 24 h (D1) and 48 h (D2) of treatments with vehicle, GPE, GH, 
and GPE + GH (same doses as those described above). * p < 0.05 vs. vehicle. Scale bars 500 µm. 
2.3. Cell Migration Induced by GPE or GH 
Besides to being useful for studying cell proliferation, the wound-healing assay is a 
straightforward method to study cell mobility in vitro [27]. As depicted in Figure 3A–D, the creation 
of a scratch on the confluent cell monolayer stimulated the migration of the cells on the edge of the 
gap towards the opening with a clear mesenchymal behavior. This migration was significantly 
increased by either GPE or GH treatment, since both the wound closure and the number of cells 
present in the gap were higher in either GPE-treated or GH-treated cells as compared with vehicle-
treated cells. However, also in this case, the combined administration of GPE + GH did not induce a 
greater effect that any isolated treatment. Interestingly, despite the increase in the number of cells 
present in the gap induced by the treatments, no differences were found in the number of BrdU+ cells 
among the four experimental groups, thus indicating that filling the gap mainly depends on 
migrating rather than proliferating cells (Figure 3B). To further ascertain this possibility, a wound 
healing assay was performed in the presence of mitomycin C, a chemotherapeutic antibiotic that, 
reportedly, inhibits cellular growth [28]. In keeping with our hypothesis, inhibition of cell 
proliferation did not significantly modify the effect of either GPE or GH treatment (or their 
combination) on the wound closure (Figure 3E,F). 
Figure 2. Both Gly-Pro-Glu (GPE) and growth hormone (GH) treatment enhance cell proliferation.
(A,B) Cells were serum-starved for 48 h and then treated with GPE (100 µM), GH (500 ng/mL),
or GPE + GH every 24 h for 2 days. Control cells were treated with vehicle. (A) Each bar represents the
mean + SEM (Standard Error of the Mean) of two independent experiments (n = 20); (B) Representative
images of results are shown in panel A; (C–D2) Cells were serum-starved for 48 h and a scratch
wound healing assay was performed (see methods for further details); (C,E) Each bar represents the
mean + SEM of three independent experiments (n = 30); (D1,D2) Representative images of results are
shown in panels (C,E) after 24 h (D1) and 48 h (D2) of treatments with vehicle, GPE, GH, and GPE + GH
(same doses as those described above). * p < 0.05 vs. vehicle. Scale bars 500 µm.
2.3. Cell Migration Induced by GPE or GH
Besides to being useful for studying cell proliferation, the wound-healing assay is a straightforward
method to study cell mobility in vitro [27]. As depicted in Figure 3A–D, the creation of a scratch on
the confluent cell monolayer stimulated the migration of the cells on the edge of the gap towards the
opening with a clear mesenchymal behavior. This migration was significantly increased by either GPE
or GH treatment, since both the wound closure and the number of cells present in the gap were higher
in either GPE-treated or GH-treated cells as compared with vehicle-treated cells. However, also in
this case, the combined administration of GPE + GH did not induce a greater effect that any isolated
treatment. Interestingly, despite the increase in the number of cells present in the gap induced by the
treatments, no differences were found in the number of BrdU+ cells among the four experimental
groups, thu indic ting that filli g the gap mainly depends on migrating rather than proliferating
cells (Figure 3B). To further scertain this possibility, a wound healing assay was performed in the
presence of mitomycin C, a chemo herapeutic antibiotic that, reportedly, inhibi s cellular growth [28].
In keeping with ur hyp thesis, inhibition of cell proliferation did not significantly modify the effect
of either GPE or GH treatment (or their combination) on the wound closure (Figure 3E,F).
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(n = 30). * p < 0.05 vs. basal. Black rectangles in (C,F) indicate the zone where cells were measured. 
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phosphorylated Akt. This effect was observed as soon as 5 min after the treatment, with the maximal 
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Figure 3. Both GPE and GH stimulate cell migration in scratch wound-healing assay. (A,B) Cells
were serum-starved and treated with GPE (100 µM), GH (500 ng/mL), or GPE + GH every 24 h
for 2 days. Control cells were treated with vehicle. (A) Percentage of wound closure after 48 h of
treatment. * p < 0.05 vs. vehicle; (B) Total number of cells and cells BrdU+ inside the lesion after 48 h of
treatment. * p < 0.05 vs. vehicle. Results are representative of three independent experiments (n = 30);
(C,D) R presentative images of results are shown in panels (A,B); (E) Cells were serum-starved and
treate as indicated above in the presence of mitomycin C or vehicle, and the total number of cells inside
the lesion was determined after 48 h. Results a representative of three indepe dent xperiments
(n = 30). * p < . asal. Black rectangles in (C,F) indica e the zone where cells wer measured.
Images in ( ) c t ptical microscopy, without sta ing. Time 0 in (C,D) shows the basal
situation, before co i t t t. it C: Mitomycin C. Scale bars 500 µm (C) and 50 µm (D).
2.4. GPE Signaling Pathways
Once we demonstrated these biological effects of GPE on NSCs, we intended to delineate their
mechanisms of action. To this end, we investigated two signaling pathways classically involved in the
control of cell proliferation, such as the PI3K-Akt and ERK pathways. As shown in Figure 4, treatment
of monolayer cultures of NSCs with GPE induced a prompt rise in the levels of phosphorylated
Akt. This effect was observed as soon as 5 min after the treatment, with the maximal activation
observed at time 15 min (Figure 4A). In contrast, when cells were treated with GPE in the presence of
LY294002, a selective inhibitor of PI3K, Akt phosphorylation was completely prevented (Figure 4D).
GPE treatment also induced the phosphorylation of Akt, with a similar pattern of activation (Figure 4A).
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Also in this case, GPE-induced phosphorylation was abrogated when GPE was given in the presence
of U0126, a highly selective inhibitor of both MEK1 and MEK2 (Figure 4E).
Similar results were obtained when cells were treated with GH (Figure 4B). In keeping with
previous reports in hippocampal neural precursors [24], GH elicited the activation of both PI3K-Akt
and ERK signaling pathways (Figure 4B) that was prevented using selective inhibitors (Figure 4D,E).
As also occurred when we investigated the effect of combined administration of GPE and GH on
cell proliferation and migration, no differences were observed on either Akt or ERK phosphorylation
when both drugs were given simultaneously, as compared with their independent effects (Figure 4C).
Activation of either Akt or ERK signaling induced by GPE + GH was also prevented in the presence of
specific inhibitors (Figure 4D,E).
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Cells were serum-starved and treated with GPE (100 µM), H (5 ng/mL), or GPE + GH for the
indicated tim s. (A–C) Akt, phospho-Akt, ERK, phospho-ERK, and glyceraldehyde 3-phosphate
dehydrogenas (GAPDH) immunoreactivities were det rmined by western lot; (D) Densitometric
analysis f r sults presented in panels (A,C). Results are shown as the pAkt/Akt (upper) or ERK/ERK
ratio (lower); ( ,F) Akt and ERK phosphorylatio were investigated in the presence of the specific
inhibitors LY294002 (LY) and U0126 (U). C+ indicates the positive control (not serum-starved cells);
(G) Densitometric analysis of results presented in panels A to C. Results are shown as the pAkt/Akt
(upper) or pERK/ERK ratio (lower).
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2.5. The Role of ERK and Akt on Cell Proliferation and Migration
To gain further evidence about the role of Akt and ERK signaling pathways on GPE effects
on NSCs, we envisaged the effect of the blockade of these paths on cell proliferation by using the
wound-healing assay (Figure 5). As indicated above, GPE, GH, or GPE + GH treatment significantly
increased the number of BrdU+ cells present at the edges of the wound. However, this effect was
dramatically decreased in all cases by treating the cells with either LY294002 or U0126 (Figure 5A,B).
Similar results were obtained when the number of cells filling the gap was investigated. All treatments
increased the number of cells observed within the gap, an affect that was thwarted by using the specific
inhibitors (Figure 5C). Overall, these findings suggest that both ERK and Akt are involved in the
proliferation and migration induced by either GPE or GH treatment in NSCs.
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under these experimental conditions. Pharmacological blockade of PI3K/Akt signaling resulted in a 
significant 4-fold increase in the number of apoptotic cells, that was not counteracted by any of the 
treatments tested (GPE, GH, or GPE + GH). Similarly, the blockade of the ERK pathway with U0126 
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Figure 5. The PI3K/Akt and ERK pathways are involved in the proliferative effect of both GPE and GH.
Cells were serum-starved for 48 h and a scratch wound healing assay was performed (see methods for
further details). Cells were then treated for 24 h with GPE (100 µM), GH (500 = ng/mL), or GPE+GH,
in the presence of LY294002, U0126, or vehicle. BrdU (10 mM) was given 2.5 h before the end of the
treatments and BrdU+ cells were detected by immunocytochemistry. (A) Number of BrdU+ cells at
the edge of the wound and within the gap. Each bar represents the mean + SEM of two independent
experiments (n = 20). * p < 0.05 vs. vehicle; ** p < 0.01 vs. vehicle, GPE, GH, and GPE + GH; (B) Total cells
(BrdU+ and BrdU−) present within the gap. Each bar represents the mean + SEM of two independent
experiments (n = 20). * p < 0.05 vs. vehicle; (C) Representative images of data shown in panels (A,B).
LY = LY294002. U = U0126. Scale bars 500 µm.
2.6. The Role of ERK and Akt on Cell Survival
The involvement of Akt and ERK signaling on GPE actions was further explored by investigating
their role on cell survival. As Figure 6 depicts, either GPE or GH treatment, as well as their combination
sharply, reduced the number of apoptotic cells as compared with controls, although no statistical
significance was achiev d, probably because of the low number of apoptotic cells existing under these
experimental conditions. Pharmacological blockade of PI3K/Akt signaling resulte in a significant
4-fold increa e in the number of apoptotic cells, that was not ounteracted by any of the treatments
teste (GPE, GH, or GPE + GH). Similarly, the lockade of the ERK pathway with U0126 induced
a 3-fold significant increase in the number of apoptotic cells. Also in this case, stimulation of apoptotic
cell death was not modified by either GPE or GH or their combination. In all, these results reinforce
the role of Akt and ERK in both GPE and GH signaling.
Int. J. Mol. Sci. 2017, 18, 1280 7 of 14
Int. J. Mol. Sci. 2017, 18, 1280  7 of 14 
 
 
Figure 6. Blockade of PI3K K/Akt or ERK pathways results in activation of apoptotic cell death of 
NSCs that is not counteracted by either GPE or GH treatment. Cells were seeded in 24-well plates and 
treated with GPE (100 µM), GH (500 ng/mL), GPE + GH (100 µM and 500 ng/mL, respectively) or 
vehicle every 8 h for 1 day, in the presence of LY294002, U0126 or dimethyl sulfoxide (DMSO) 
(vehicle). Cells were stained with Hoestch 33,258 (1 µg/µL) and propidium iodide (1 µg/µL), and cell 
morphology was examined under a fluorescence microscope. (A) Each bar represents the mean + SEM 
of three different experiments in triplicate. * p < 0.05 vs. vehicle, # p < 0.05 vs. respective control (i.e., 
LY+GPE vs. GPE, etc.); (B) Representative images of results are shown in panel A. Scale bars 500 µm. 
2.7. Blockade of the NMDA Receptor and GPE Signaling Pathways 
Finally, since the mechanism underlying the actions of GPE remains unclear, we investigated 
the possible involvement of the NMDA receptor, one of the proposed mechanisms by which GPE 
might act, by using a selective inhibitor of NMDA activation. Reportedly, GPE interacts with NMDA 
receptor, but both antagonist and weak-agonist effects have been described. As Figure 7 depicts, GPE 
treatment promotes the phosphorylation of both Akt and ERK in the presence of MK801. 
Furthermore, blockade of NMDA receptor by MK801 treatment also induced a sharp increase in the 
phosphorylation of both Akt and ERK, similar to that observed after GPE treatment. Overall, these 
results suggest that the effects GPE effects may also be mediated by its ability to bind and blockade 
the NMDA receptor. 
 
Figure 7. Blockade of NMDA receptors promotes Akt and ERK phosphorylation. (A) Cells were 
serum-starved for 48 h and then treated with MK-801 (100 µM, +) or vehicle (-) for 2 h. At the end of 
the treatment, cells were challenged during 15 min with GPE (100 µM, +) or vehicle (-). Serum-treated 
and serum-starved (48 h) cells were used as positive (1) and negative (2) controls, respectively; (B) 
Densitometric analysis of results are presented in panel A. Results are shown as the pAkt/Akt (upper) 
or pERK/ERK ratio (lower). 
Figure 6. Blockade of PI3K K t r RK pathways results in activation of a optotic cell death of
NSCs that is n t c teracted by either GPE or GH treatment. Cells were seeded in 24-well plates
and treated with GPE (100 µM), GH (500 ng/mL), GPE + GH (100 µM and 500 ng/mL, respectively)
or vehicle every 8 h for 1 day, in the presence of LY294002, U0126 or dimethyl sulfoxide (DMSO)
(vehicle). Cells were stained with Hoestch 33,258 (1 µg/µL) and propidium iodide (1 µg/µL), and cell
morphology was examined under a fluorescence microscope. (A) Each bar represents the mean + SEM
of three different experiments in triplicate. * p < 0.05 vs. vehicle, # p < 0.05 vs. respective control
(i.e., LY+GPE vs. GPE, etc.); (B) Representative images of results are shown in panel A. Scale bars 500 µm.
2.7. Blockade of the NMDA Receptor and GPE Signaling Pathways
Finally, since the mechanism underlying the actions of GPE remains unclear, we investigated the
possible involvement of the NMDA receptor, one of the proposed mechanisms by which GPE might
act, by using a selective inhibitor of NMDA activation. Reportedly, GPE interacts with NMDA receptor,
but both antagonist and weak-agonist effects have been described. As Figure 7 depicts, GPE treatment
promotes the phosphorylation of both Akt and ERK in the presence of MK801. Furthermore, blockade
of NMDA receptor by MK801 treatment also induced a sha p increase in the phosphorylation of both
Akt and ERK, similar to that observed after GPE treat ent. Overall, these results suggest that the
effects GPE effects may also be mediated by its ability to bind and blockade the NMDA receptor.
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Figure 7. Blockade of NMDA receptors pro otes Akt and ERK phosphorylation. (A) Cells were
serum-starved for 48 h and then treated with MK-801 (100 µM, +) or vehicle (-) for 2 h. At the
end of the treatment, cells were challenged during 15 min with GPE (100 µM, +) or vehicle (-).
Serum-treated and serum-starved (48 h) cells were used as positive (1) and negative (2) controls,
respectively; (B) Densitometric analysis of results are presented in panel A. Results are shown as the
pAkt/Akt (upper) or pERK/ERK ratio (lower).
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3. Discussion
Several reports have demonstrated that GPE exerts a neuroprotective effect in both in vitro
and in vivo systems. Thus, administration of GPE protects neurons from NMDA-induced toxicity
rat cortical slices, while central administration of GPE reduces the extent of cortical infarction in
several models of hypoxia-ischemia in rats [15–18,29]. GPE has also been proved to be effective in
preventing some of the clinical outcomes present in several animal models of degenerative diseases
and, more recently, to exert an anti-depressant activity in mice [19–22]. In this study, we have described
a novel effect of GPE in neural cells, such as the stimulation of cell proliferation and, to some extent,
cell migration. Altogether, these findings would support a role for GPE not only in neuroprotection
but also in neural repair.
Neural progenitors are cells that are capable of dividing a limited number of times and have
the capacity to differentiate into a restricted repertoire of neuronal and glial cell types. Due to these
characteristics, neural progenitors may be used to replace the neuronal loss that is the hallmark
of several CNS diseases [30]. In this report, we have found that GPE administration promotes the
proliferation and, to a lesser extent, the migration of neural progenitors. This effect was observed
either in cells growing under basal conditions or as a response to mechanical damage induced by using
an in vitro model of wound repair. Interestingly, the results obtained in this study are very similar
to those observed when GH, a well-known promoter of neural regeneration, was used under the
same experimental conditions. This resemblance comprises both the biological effects and biochemical
mechanisms involved. In fact, both compounds yield comparable results on both cell proliferation
and migration in all the experimental settings investigated and, intriguingly, no additive effect was
observed when given together. Similarly, activation of either ERK or Akt signaling pathways was
almost identical for both hormones. This includes both the maximal activation achieved and the
time-course of activation observed. Altogether, these equivalent results suggest that GPE and GH
are activating the same signaling pathways (namely ERK and PI3K-Akt) to promote cell proliferation
and migration. In fact, these signaling mechanisms are among the best characterized in the regulation
of cell proliferation, differentiation, and survival in response to a wealth of hormones and growth
factors in many cell types [31–33]. Therefore, it is tempting to speculate that GPE treatment may be
used, as occurs with GH, to promote neural repair in vivo. However, since GPE has an extremely
short mean-life in vivo, further studies will be necessary to investigate whether the GPE analogues
with longer half-lives that are currently being tested in clinical trials [34] show similar effects on cell
proliferation and migration. In addition, the effects of novel IGF-I-derived smaller peptides are now
being studied in human patients [35].
Despite the accumulating evidence supporting a role for GPE in CNS protection and repair,
the molecular mechanisms underlying these effects remain unclear. Although GPE sequence is
essential for IGF-1 binding to IGF-1 binding proteins, it is presently clear that GPE does not interact
with IGF-1 receptor [14]. Owing to its glutamate residue, the possibility that GPE could act through
the N-methyl-D-aspartate (NMDA) receptor has also been raised. In this regard, radioligand-binding
studies have suggested that GPE binds to NMDA receptors in Müller glia and activation of NMDA
receptor mediates the mitogenic effects of GPE in these cells [36]. In contrast, Sara et al. [11] showed
that GPE inhibits glutamate binding to the N-methyl-D-aspartate (NMDA) receptor, thus inducing
the release of acetylcholine from rat cortical slices and, to a lesser extent, the release of dopamine
from striatum. Furthermore, the neuroprotective effect induced by GPE is similar to that of MK801,
a‘noncompetitive NMDA receptor antagonist [11], which has also been proved to promote ERK and
Akt phosphorylation in a similar fashion to that of GPE (this study).
On the other side, it has been reported that the prevention of neuronal death showed by GPE is
not directly related to its affinity by glutamate receptors [37]. Indeed, GPE has been recently shown to
have a very low binding affinity for NMDA, thus making it unlikely that NMDA is its physiological
receptor [38]. While one possible explanation for these discrepancies may be differences in the dose
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of GPE and/or the experimental settings used, it seems to be clear that further experiments are still
necessary to unveil the physiological receptor mediating GPE actions.
Although our results do not allow us to determine the nature of the GPE receptor, the fact that
we have observed a rapid phosphorylation for both, and different, signaling pathways (ERK and Akt)
suggests that the activation of these is a direct effect of receptor stimulation rather than a cross-talking
mechanism. At present, there is strong evidence supporting a relationship between NMDA receptor
and both ERK and Akt activation in neural cells. Thus, agonist binding of the NMDA receptor increases
postsynaptic intracellular [Ca2+] and activates the ERK pathway in neurons through a direct interaction
of the receptor with Ras protein specific guanine nucleotide releasing factor 1 (RasGRF1) [39,40].
Similarly, activation of Akt has also been reported in cortical neurons through a mechanism that
mirrors ERK activation and may also involve Ca2+ influx [41]. Altogether, these findings might
indicate the possibility that NMDA receptor is also involved in the GPE-induced activation of ERK
and Akt signaling in NSCs. However, we also report here that inhibition of the NMDA receptor
with a non-competitive agonist results in activation of both signaling pathways in a fashion that
resembles that observed after GPE treatment. This result makes it unlikely that GPE is stimulating
NMDA receptor to promote ERK and Akt activation (and, therefore, cell proliferation and migration),
and suggests that the effect of GPE may depend on NMDA receptor blockade, as previously proposed
by Sara et al. [11]. In fact, the existence of a NMDA receptor-mediated inhibitory pathway that functions
to attenuate or shut-off ERK and Akt signaling has also been previously reported in neurons [42].
On this basis, it seems conceivable that blockade of this pathway by GPE would result in activation of
ERK and Akt signaling. While this NMDA receptor-mediated inhibitory pathway does not appear to
predominate in neurons, it has been proposed to be selectively coupled to activation of extrasynaptic
NMDA receptors. Since our studies are not performed in neurons but in neural progenitors, it is
possible to speculate that, at odds with neurons, NMDA receptor-mediated inhibitory pathway is
predominating in these cells. Another possibility is that GPE actions may occur as a consequence
of indirect effects on the NMDA receptor. Moreover, since we did not observe any additive effect
when cells were treated with GPE + GH, the possibility exists that GPE and GH share a mechanism for
activating ERK and Akt through different receptors.
Another possibility, not tested in our study, is that GH might induce the expression of IGF-I in
the cells we cultured, and this newly-formed IGF-I could have originated GPE, therefore explaining
the similar effects of GH and GPE and the lack of synergism between them. In fact, it has been
demonstrated [43] that GH induces the expression of IGF-I in human fetal forebrains. However,
the fast effects of both GH and GPE on the phosphorylation of Akt and ERK makes such a possibility
quite unlikely.
In summary, our results show that GPE promotes the proliferation and migration of neural
progenitors through a mechanism that involves the activation of ERK and PI3K-Akt pathways,
thus supporting a possible role for GPE (or any of its analogues) for promoting neural repair
in vivo. This possibility may be overestimated because in this study we used embryonic stem cells,
whose potential for neural regeneration is quite different to that of adult stem cells. However,
some preclinical studies [42,44,45] and clinical trials currently in course indicate that GPE or its
derivatives possess important beneficious effects as neuroprotective and neuroregenerative factors.
4. Materials and Methods
4.1. Cell Cultures and Treatments
Monolayer cultures of mouse embryonic NSCs were established from 13.5 days C57BL/6 mice
embryos. The care and use of all experimental animals was in accordance with institutional guidelines
(EU Directive 2010/63/EU for animal experiments). It was approved by the Ethical Committee for
Animal Research of the Xunta de Galicia (15005AE/11/FIS 02/VMAV/1, 14/October/2011). Briefly,
cells were dissociated by mechanical shearing followed by filtration through a 40-micron mesh.
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Cells were then plated in Falcon polystyrene culture dishes (BD Biosciences, Madrid, Spain) and grown
in Dulbecco’s modified Eagle’s medium (DMEM, Sigma-Aldrich, Madrid, Spain) supplemented with
10% fetal bovine serum (FBS) (Thermo Fisher Scientific, Madrid, Spain), 1% L-glutamine, and 1%
penicillin/streptomycin (all from Thermo Fisher Scientific). Formation of neurospheres was induced
by growing the cells in DMEM supplemented with 1% Gibco B27 supplement, 10 ng/mL epidermal
growth factor (EGF), 10 ng/mL basic fibroblast growth factor-2 (bFGF-2) (all from Thermo Fisher
Scientific), 100 U/mL penicillin, and 100 µg/mL streptomycin. Development of monolayer cultures
from neurospheres was achieved by placing the neurospheres in DMEM supplemented with 10%
FBS, 1% L-glutamine, and 1% penicillin/streptomycin. All cultures were maintained at 37 ◦C in
a humidified atmosphere of 5% CO2. Note that these cultures were composed of a mixed population
of progenitor and differentiated neural cells.
Except where indicated, all experiments were performed in cells serum-starved (0% FBS) for 48 h.
Cells were then treated with GPE (Bachem AG, Bubendorf, Switzerland, 100 µM), GH (Humatrope,
Eli Lilly and Co., Madrid, Spain, 500 ng/mL), or GPE + GH. GPE dose was determined as the minimal
dose that was able to induce cell proliferation. GH dose was established according with previous
reports [24,46]. Control cells were treated with vehicle. The antimitotic drug mitomycin was purchased
from Sigma and used at 5 µM. The PI3K-Akt and ERK signaling pathways inhibitors (LY294002
and U0126, respectively) were purchased from Cell Signaling Technology (Danvers, Werfen/Izasa,
Hospitalet de Llobregat, Spain), and used at 10 µM. The selective non-competitive NMDA receptor
antagonist, MK-801, was purchased from Sigma-Aldrich and used at 100 µM.
4.2. Immunocytochemistry
Approximately 5 × 103 cells were seeded in glass coverslips, placed in 24-multiwell plates,
and incubated for 24 h as described above. Cells were then fixed in 96% ethanol for 1 h, rinsed in
posphate-buffered saline (PBS), and permeabilized by adding 250 µL of 0.1% Triton X-100, 0.3% bovine
serum albumin (BSA) for 1 h. After rinsing the cells three times in PBS, an overnight incubation
at 4 ◦C was performed with the following primary antibodies: anti-glial fibrillary acidic protein
(GFAP) (polyclonal, Dako, Agilent Technologies, Madrid, Spain; ready to use), anti-myelin basic
protein (MBP) (polyclonal, Dako, Agilent Technologies; dilution 1:2000), anti-NeuN (monoclonal,
Merk Millipore, Madrid, Spain; dilution 1:200), and anti-SOX2 (polyclonal, Seven Hills Bioreagents,
Cincinnati, OH, USA; dilution 1:1000). Positive cells were detected with a universal second antibody kit
that uses a peroxidase-conjugated labeled-dextran polymer (Envision Plus, Dako, Agilent Technologies,
Santa Clara, CA, USA) and photographed with an Olympus BX43 camera (Olympus Optical Co.,
Tokyo, Japan).
4.3. Cell Proliferation Assays
Cells were seeded at 106 cells/mL in poly-L-lysine-coated slides (1 mL/slide) and maintained for
24 h. Cells were the serum-starved for 48 h before being treated with GPE, GH, or GPE + GH every
24 h for 2 days. Control cells were treated with vehicle. BrdU (10 mM, Sigma-Aldrich) was given
45.5 h after the beginning of the treatments and maintained for 2.5 h. BrdU+ cells were detected by
immunocytochemistry using a monoclonal antibody (BD Biosciences, dilution 1:2000). Representative
images were captured with an Olympus DP72 camera, and the number of BrdU+ cells was quantified
in 10 random fields per slide.
4.4. Wound-Healing Assays
The wound healing process entails the migration and proliferation of different cell types in vitro.
To perform the wound-healing assay, cells were seeded at approximately 1 × 105 per slide and
incubated as previously described. Using a plastic pipette tip, a wound field was created with
a defined gap of 1 mm, and cells were then treated with GPE, GH, GPE + GH, or vehicle, as indicated
above. BrdU+ cells were detected by immunocytochemistry, as previously indicated, and random
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fields were photographed with an Olympus DP72 camera. The number of cells (total and BrdU+)
within the gap and at the edge of the lesion was quantified with the image J software (https://imagej.
nih.gov/ij/index.html). In addition, the area of the lesion was also evaluated as previously reported
by Latifi-Pupovciet et al. [47].
4.5. Western Blot
For phospho-ERK 1/2 and phospho-Akt determination, cells were serum-starved and treated as
described. Cells were then collected and lysed by adding RIPA buffer with sodium orthovanadate
(10 µL/mL, Sigma), Phenylmethylsulfonyl fluoride (PMSF) (10 µL/mL), aprotinin (20 µL/mL),
and NaF 50 mM (all from Sigma). Cell extracts were resolved on 10% sodium dodecyl sulfate
polyacrylamide gel electrophoresis (SDS-PAGE) and electro blotted onto a nitrocellulose membrane
(Trans-Blot Transfer Medium 0.2 µm, BioRad Laboratories, Madrid, Spain). Primary antibodies
against Akt (dilution 1:1000), phospho Akt (dilution 1:1000), ERK 1/2 (dilution 1:10,000), phospho
ERK 1/2 (dilution 1:1000) (all from Cell Signaling Technology), and glyceraldehyde 3-phosphate
dehydrogenase (GAPDH) (Santa Cruz Biotechnology, Heidelberg, Germany; dilution 1:5000) were
applied overnight at 4 ◦C or 4 h at room temperature. Immunoreactive bands were detected with
a western-light chemiluminescence detection system (ECL, APBiotech, Little Chalfont, UK) and
photographed (HyperfilmECL, APBiotech, IBM, Madrid, Spain). Band density was evaluated with the
Image J software.
4.6. Determination of Cell Apoptosis
Apoptotic cell death was determined by nuclear staining with Hoestch 33258 (1 µg/µL, Thermo
Fisher Scientific) and propidium iodide (Merk Millipore, 1 µg/µL). Briefly, cells were seeded in
24-multiwell plates and treated with GPE (100 µM), GH (500 ng/mL), GPE + GH (100 µM + 500 ng/mL),
or vehicle every 8 h for 1 day, in the presence of LY294002, U0126, or DMSO (vehicle). Twenty minutes
before the end of the treatment period cells were stained with Hoestch 33,258 and propidium iodide and,
after rinsing, cell morphology was examined under an Olympus fluorescence microscope (TH4-200)
with the appropriate filter combination. Cells were scored for apoptosis by their nuclear morphology
(shrinkage, condensation, and fragmentation) and the higher intensity of blue fluorescence.
4.7. Statistical Analysis
Statistical analysis was performed with one-way ANOVA and Dunnett´s multiple comparisons
test. Statistical significance was established at p < 0.05.
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